Advice
Following a full submission.
Tacrolimus (Prograf) is accepted for restricted use within NHS Scotland for the prophylaxis of transplant rejection in heart allograft recipients. It has shown comparable efficacy to ciclosporin-based regimens in prevention of acute rejection. It is restricted to use in patients where ciclosporin is not suitable.
Download detailed advice43KB (PDF)
Medicine details
- Medicine name:
- tacrolimus, 5mg/ml concentrate for infusion and 0.5mg, 1mg, 5mg hard capsules (Prograf)
- SMC ID:
- 346/07
- Indication:
- Prophylaxis of transplant rejection in heart allograft recipients
- Pharmaceutical company
- Astellas Pharma Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 12 February 2007